AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Was ist los? Short Sqeeze? Schon 625 K stück.

11,05 M Stück

Entschuldige 1,05 M

5.08 M

Short % verringert sich langsam.

https://abcellera.com/post/sitc2024/

AbCellera presents data on applications of T-cell engager platform at SITC TheFly Nov 07, 2024, 04:10 PM AbCellera (ABCL) announced new data on its T-cell engager, or TCE, platform, to be presented as a poster at the Society for Immunotherapy of Cancer, or SITC, 39th Annual Meeting. AbCellera’s presentation describes strategies to address key challenges in TCE development and preclinical characterization of TCEs against solid tumor targets B7-H4 and PSMA show tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks, the company noted. https://www.tipranks.com/news/the-fly/abcellera-presents-data-on-applications-of-t-cell-engager-platform-at-sitc?mod=mw_quote_news

AbCellera Biologics: Promising Investment with Robust Antibody Platform and Strategic Growth Plans Brian Anderson Nov 06, 2024, 09:19 AM Leerink Partners analyst Puneet Souda has reiterated their bullish stance on ABCL stock, giving a Buy rating yesterday. Puneet Souda has given his Buy rating due to a combination of factors that highlight AbCellera Biologics as a promising investment. The company possesses a robust antibody discovery platform and a substantial liquidity position exceeding $800 million, which it is utilizing to develop its internal pipeline and establish strategic partnerships. Despite limited updates in the third quarter of 2024, the company remains on track with its timelines for clinical trial applications and the first commercial lot shipment from its GMP facility. The stock is currently trading near its total liquidity, suggesting potential upside from its royalty portfolio and internal pipeline. Management anticipates providing significant preclinical data in the second quarter of 2025, which could enhance recognition of the platform’s value. Additionally, AbCellera is prioritizing its preclinical candidate molecules and carefully managing its capital deployment, believing it has sufficient capital for three years to generate clinical data and attract interest from potential partners. According to TipRanks, Souda is an analyst with an average return of -14.1% and a 34.28% success rate. Souda covers the Healthcare sector, focusing on stocks such as Illumina, Exact Sciences, and Quanterix. In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $12.00 price target. https://www.tipranks.com/news/blurbs/abcellera-biologics-promising-investment-with-robust-antibody-platform-and-strategic-growth-plans?mod=mw_quote_news

Q & A Highlights Q: Can you update us on the competitive landscape for OX40 ligand targeted therapy, particularly in light of recent data from rocatinlimab? A: Carl Hansen, CEO, explained that rocatinlimab's recent data highlights the differences between OX40 and OX40 ligand therapies. Rocatinlimab is a depleting antibody, whereas AbCellera's 575 is non-depleting. The recent data suggests that non-depleting OX40 ligand antibodies, like 575, may have an advantage. AbCellera remains optimistic about the potential of 575 in atopic dermatitis and other indications. Q: What extent of data can we expect at SITC for the T-cell engagers? A: Carl Hansen, CEO, stated that they will present updated data from the T-cell engager platform, highlighting programs demonstrating desired profiles in killing and cytokine response. They will also present work on trispecific TCEs designed for better sustained T-cell killing. Q: How many TCE programs do you think you could push forward independently without a broader partnership? A: Carl Hansen, CEO, mentioned that AbCellera has built core capabilities to develop antibody therapies and has nearly $900 million in liquidity. They anticipate advancing two to three new development candidates per year starting next year, with sufficient funding for over three years of pipeline investments. Q: Is there a requisite amount of clinical development work that needs to occur through Canadian trial sites due to government funding? A: Andrew Booth, CFO, confirmed that Phase 1 trials for molecules funded by the Canadian government will be conducted in Canada. They do not anticipate issues with this requirement for current trials and can expand to other countries if necessary. Q: Can you provide more details about ABCL635, its target market, and competitiveness? A: Carl Hansen, CEO, stated that ABCL635 is a first-in-class antibody for endocrine or metabolic disorders targeting a multipass transmembrane protein. The addressable market is estimated to exceed $2 billion, but further details will be disclosed upon CTA approval. https://www.gurufocus.com/news/2582653/abcellera-biologics-inc-abcl-q3-2024-earnings-call-highlights-navigating-challenges-with-strategic-developments?r=4bf001661e6fdd88d0cd7a5659ff9748

Bald sind Wir wie ich es gesagt habe unter 2 doller

Net mal 8 Millionen erreicht 😵‍💫

Wenn trump gewinnen sollte sehen wir maximal 5 Euro dann wieder Berg ab

So ein drecksladen ohne witz

Steht Was an oder leuten in 2 Jahren in Insolvenz Glocken 😁

Was steht an bei diesem.abficker wann wird Was wieder entdeckt oder zusammen arbeiten gemacht??